<DOC>
	<DOCNO>NCT02234427</DOCNO>
	<brief_summary>This clinical trial examine effect 2-week aspirin therapy platelet gene expression person high-risk develop heart attack due family history early-onset coronary artery disease</brief_summary>
	<brief_title>Pharmacogenomics Antiplatelet Response</brief_title>
	<detailed_description>In clinical trial select individual GeneSTAR cohort base platelet function . Equal number individual select race gender low high platelet aggregation . We baseline platelet function perform baseline platelet gene expression examine . Participants give 2-week supply aspirin ( 81 mg/daily ) examine end 2-weeks platelet aggregation study repeat platelet gene-expression ( use RNA-seq ) . The ultimate goal examine platelet gene expression difference due aspirin across different gender , race , platelet-aggregation group .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>4575 year GeneSTAR participant No personal History Coronary Artery Disease Women postmenopausal Women use reliable method contraception , history tubal ligation , IUD take OCP Taking aspirin prescribe physician weight &lt; 60 kg History recent current bleeding allergy aspirin history adverse event aspirin serious comorbid condition ( AIDS , active cancer ) high blood pressure ( &gt; 160/95 ) History gastrointestinal ulcer/bleeding Mental incompetence make decision participate .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>aspirin , atherosclerosis</keyword>
</DOC>